Abstract: The invention provides a two-step push-on switch in which first and second switches are sequentially turned ON as a result of a depressing operation, and a movable contact plate configured by a metal plate spring is fixed by an adhesive tape onto a circuit board without deteriorating the operation characteristics of the movable contact plate. A spacer 20 is placed around the movable contact plate 1 on the circuit board 8, and a continuous or discontinuous tape-sticking face 21 which is lower in level than the top of a center plate portion 3 and higher than a peripheral plate portion 2 is formed by the spacer 20 around the movable contact plate 1, thereby preventing the adhesive tape 9 or 19 from sticking to the peripheral plate portion 2. In the adhesive tape 19, nonadhesive portions 27, 27 are formed in places opposing to parts of the peripheral plate portion 2 of the movable contact plate 1 excluding at least the connecting portions with the connecting plate portions 4, 4, respectively.

Abstract: The invention provides a movable contact for a two-step push-on switch which can realize an excellent sense and a long life period while decreasing the width, even on a flat stationary-contact forming surface of a printed circuit board, a flexible printed circuit board or the like, and also a two-step push-on switch. A movable contact has: a rectangular annular peripheral plate portion 2; an oval center plate portion 3 which is upward inflatingly curved; and a pair of connecting plate portions 4, 4 which connect an inner edge of the peripheral plate portion 2 to an outer edge of said center plate portion 3 on a center line X which is parallel to long side portions 2a, 2a of said peripheral plate portion 2. The movable contact is disposed on a flat stationary-contact forming surface of a printed circuit board, a flexible printed circuit board, or the like, and an adhesive tape 9 for fixing the movable contact is bonded from a side of the upper face, thereby configuring a push-on switch.

Abstract: A pushbutton switch (1) includes a fixed contact portion (3) provided on a substrate (2) and an elastically deformable movable contact portion (4) provided in opposition to a surface of the fixed contact portion, the movable contact portion being configured as a dome-like portion forming a greater gap relative to the surface of the fixed contact portion at a center portion of the surface than at a peripheral portion of the surface.

Abstract: To provide novel compounds relating to retinoid which can substitute for retinoic acid used for preventing and treating several diseases and having antagonism against retinoid. Heterocyclic compounds represented by the general formula (1-I) or physiologically acceptable salts thereof: Z—(CR3═CR2)n—COOR1  (1-I) Compounds represented by the general formula (2-I) or physiologically acceptable salts thereof: The compounds according to the present invention exhibit extremely high ability to bind RARs and are effective for treating various kind of diseases such as abnormality in cornification and rheumatoid arthritis.

Abstract: Mono- or polyenic carboxylic acid derived compounds of the formula (1-I) or a physiologically acceptable salt thereof: Z—(CR3═CR2)n—COOR1  (1-I) wherein R1 is hydrogen or a carboxyl-protecting group; R2 and R3 are each independently hydrogen, halogen, linear lower alkyl, branched lower alkyl linear lower alkoxy, branched lower alkoxy or aryl, m is 1 to 3 and Z is a group or their salts have the potent ability to bind to retinoic acid receptors thus useful in treating psoriasis and rheumatoid arthritis.

Abstract: To provide novel compounds relating to retinoid which can substitute for retinoic acid used for preventing and treating several diseases and having antagonism against retinoid. Heterocyclic compounds represented by the general formula (1-I) or physiologically acceptable salts thereof:Z--(CR.sup.3 .dbd.CR.sup.2).sub.n --COOR.sup.1-- (1-I)Compounds represented by the general formula (2-I) or physiologically acceptable salts thereof: ##STR1## The compounds according to the present invention exhibit extremely high ability to bind RARs and are effective for treating various kind of diseases such as abnormality in cornification and rheumatoid arthritis.

Abstract: Compounds of the formula and compounds of the formula ##STR1## or their salts have the potent ability to bind to retinoic acid receptors thus useful in treating psoriasis and rheumatoid arthritis.

Abstract: Compounds of the formula ##STR1## and compounds of the formula ##STR2## or their salts have the potent ability to bind to retinoic acid receptors thus useful in treating psoriasis and rheumatoid arthritis.

Abstract: A heterocycle-containing carbonic acid derivative represented by the following general formula (I): ##STR1## or a physiologically acceptable salt thereof which exhibits an excellent preventive and therapeutic effect against various diseases, and an intermediate which is useful for the production of the heterocycle-containing carbonic acid derivative.

Abstract: Sulfonamide compounds of formula (I) or a pharmacologically acceptable salt thereof: ##STR1## exhibit excellent antitumor activity and low toxicity.

Abstract: Sulfonamide compounds of the formula or pharmacologically acceptable salts thereof: ##STR1## wherein: R.sup.1 is a hydrogen atom, halogen atom, lower alkyl group, lower alkoxy group, hydroxyl group, nitro group, phenoxy group, cyano group, acetyl group, amino group or a protected amino group; R.sup.2 and R.sup.3 may be the same or different from each other and each is a hydrogen atom, halogen atom, lower alkyl group or lower alkoxy group; R.sup.4 and R.sup.7 may be the same or different from each other and each is a hydrogen atom or a lower alkyl group; R.sup.5 and R.sup.6 may be the same or different from each other and each is a hydrogen atom, halogen atom, lower alkoxy group, amino group or amino group substituted with a lower alkyl or a phenyl group; A is .dbd.CH--; B is .dbd.CH--; and E is selected from the group consisting of ##STR2## in which Q is an oxygen atom or a sulfur atom; and R.sup.

Abstract: In a linear motion slide unit, it is usable under a heavy load with high precision, or in a light load, an over-stroke amount can be made large. The linear motion slide unit comprises an elongated inner rail having high rigidity, a pair of outer rails attached to be reciprocally movable in an axial direction of the inner rail, and linear motion guides of endless track type structure disposed to be slidable with respect to the inner rail and fixed to the outer rails. A bearing body of the linear motion guide has also high rigidity, and accordingly, the balls mounted inside the endless track is applied with a large preload.

Abstract: Sulfonamide derivatives of the general formula (I): ##STR1## wherein preferably R.sup.1 represents a lower alkoxy group, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 may be the same or different from one another and each represent a hydrogen atom, halogen atom or lower alkyl group, A and B may be the same or different from each other and each represent .dbd.N-- or .dbd.CH--, E represents an aromatic 6-membered cyclic group, which may have 1 or 2 nitrogen atoms in the ring, and be substituted with 1 to 3 substituents which may be the same or different from one another with the proviso that a combination of R.sup.1 which is a hydrogen atom, lower alkyl group, nitro group or amino group which may be protected, R.sup.2 and R.sup.3 which are each a hydrogen atom, A and B which are each .dbd.

Abstract: Sulfonamide derivatives of the general formula (I): ##STR1## wherein preferably R.sup.1 represents a lower alkoxy group, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 may be the same or different from one another and each represent a hydrogen atom, halogen atom or lower alkyl group, A and B may be the same or different from each other and each represent .dbd.N-- or .dbd.CH--, E represents an aromatic 6-membered cyclic group, which may have 1 or 2 nitrogen atoms in the ring, and be substituted with 1 to 3 substituents which may be the same or different from one another with the proviso that a combination of R.sup.1 which is a hydrogen atom, lower alkyl group, nitro group or amino group which may be protected, R.sup.2 and R.sup.3 which are each a hydrogen atom, A and B which are each .dbd.

Abstract: Sulfonamide derivatives of the general formula (I): ##STR1## wherein preferably R.sup.1 represents a lower alkoxy group, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 may be the same or different from one another and each represent a hydrogen atom, halogen atom or lower alkyl group, A and B may be the same or different from each other and each represent .dbd.N-- or .dbd.CH--, E represents an aromatic 6-membered cyclic group, which may have 1 or 2 nitrogen atoms in the ring, and be substituted with 1 to 3 substituents which may be the same or different from one another with the proviso that a combination of R.sup.1 which is a hydrogen atom, lower alkyl group, nitro group or amino group which may be protected, R.sup.2 and R.sup.3 which are each a hydrogen atom, A and B which are each .dbd.

Abstract: Sulfonamide derivatives of the general formula (I): ##STR1## wherein preferably R.sup.1 represents a lower alkoxy group, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined in the specification, A and B may be the same or different from each other and each represents .dbd.N-- or .dbd.CH--, E represents an aromatic 6-membered cyclic group, which may have 1 or 2 nitrogen atoms in the ring, and may be substituted with 1 to 3 substituents which may be the same or different from one another with the proviso that a combination of R.sup.1 which is a hydrogen atom, lower alkyl group, nitro group or amino group which may be protected, R.sup.2 and R.sup.3 which are each a hydrogen atom, A and B which are each .dbd.CH-- and E which is a phenyl group which may be substituted with 1 to 3 substituents G which may be the same or different from one another is excluded, or pharmacologically acceptance salts of them.

Abstract: An azacyclooctadiene compound having the formula (1) or a pharmacologically acceptable salt thereof is novel and useful as an anti-tumor agent. ##STR1## in which R1 is --CH2R, R being hydrogen, --COCH3, --OH, --NH2, --COOH or --OCOCH3, or may form --CH2--X--Y-- together with R2; R2 is hydrogen, an alkyl having 1 to 4 carbon atoms or --COR10, R10 being hydrogen, an alkyl having 1 to 4 carbon atoms, --OR11 or --NHR11, R11 being an alkyl having 1 to 4 carbon atoms, or may form --CH2--X--Y-- together with R1; R3, R4 and R5 each are hydrogen or methyl; R6 and R7 each are hydrogen or may form the direct bond to each other; R8 is hydrogen or may form the direct bond to R7; and R9 is hydrogen, --N3, --NH2, --OCH3 or .dbd.0; X being oxygen or --NZ--, Z being hydrogen, methyl, --COCH3, --CH2COOH, --CO--CH.dbd.CH2, --CO--CH.dbd.CH--CH3, --CH2C6H5, --CH2OH, --CH2OCOCH3 or --CH2--COOC(CH3)3, Y being --SC--, --CO-- or --CH2--.

Abstract: A process for preparing human T cell hybridomas which are subculturable and produce lymphokines comprising the steps of: (1) treating a human acute leukemia cell with a protein and/or RNA synthesis inhibitor; (2) independently activating a human T cell with a mitogen or antigen; (3) fusing the thus-treated human acute leukemia cell with the thus-activated human T cell in the presence of a fusion accelerator; and (4) isolating the thus-formed hybridoma. An in vivo process for producing lymphokines using the hybridomas is also described.